YieldMax AI & Tech Portfolio Option Income ETF (GPTY) Stock Price Today
Aura AI Summary
Key Stats
- -Market Cap
- -Volume
- Income / Options OverlaySector
- $50.5252W High
- $34.7352W Low
- -Typical Hold Time
- -Enterprise Value
- -Div Yield
- -Trading Activity
Track YieldMax AI & Tech Portfolio Option Income ETF (GPTY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, YieldMax AI & Tech Portfolio Option Income ETF has traded between a low of $34.73 and a high of $50.52, highlighting its annual price range. Buy and sell YieldMax AI & Tech Portfolio Option Income ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Most Recent News
Major stocks fall sharply amid mixed earnings and negative outlooks, signaling broader market concerns.
Several leading stocks, including SoundThinking, TSS, and ADI Global Distribution, dropped significantly due to factors like lowered revenue forecasts and disappointing quarterly results. SoundThinking fell over 25% after cutting its revenue outlook ...

Definitive Healthcare posts a stellar 41.44% ROIC, far surpassing its 5.78% capital cost.
Definitive Healthcare Corp. stands out with a remarkable Return on Invested Capital (ROIC) of 41.44%, significantly exceeding its Weighted Average Cost of Capital (WACC) of 5.78%. This means the company generates over seven times the value for every ...

Inovio advances DNA medicine pipeline with FDA review of INO-3107 and $18.3M funding secured
Inovio Pharmaceuticals is progressing its DNA medicine pipeline with its lead candidate INO-3107 for Recurrent Respiratory Papillomatosis under FDA accelerated review, targeting a decision by October 30, 2026. The company raised $18.3 million in fund...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.